Numerous studies indicate that galectin-3 is involved in chemoresistance of various tumors, such as ovarian [3, 21], pancreatic [6], colorectal [9], thyroid [22] and prostate cancer [23], as well as osteosarcoma [10] and cholangiocarcinoma [24] and that the reduction of its expression sensitizes these cancer cells to chemotherapeutic agents. This evidence concerns the gene LGALS3 and prostate carcinoma.